DOI:https://doi.org/10.1016/j.clnu.2021.05.006

Bridget M. Kuehn

Originally published19 Jul 2021

https://doi.org/10.1161/CIRCULATIONAHA.121.055711

The Journal of Clinical Endocrinology & Metabolism, dgab468, 

https://doi.org/10.1210/clinem/dgab468

Published: 29 June 2021

Abstract

Context

While adrenal adenomas have been linked with cardiovascular morbidity in convenience samples of patients from specialized referral centers, large-scale population-based data are lacking.

Objective

Summary

Background

Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.

Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D'Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro

Diabetes Care 2021 July 12

Carlos Morillas, Luis D’Marco, María Jesús Puchades, Eva Solá-Izquierdo, Carmen Gorriz-Zambrano,
Valmore Bermúdez and José Luis Gorriz

Int. J. Environ. Res. Public Health 2021, 18(10), 5388; 

https://doi.org/10.3390/ijerph18105388

June 25, 2021

DOI: 10.1056/NEJMoa2107519

Abstract

BACKGROUND

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.